Genzyme is that rare biotech company that is both profitable and diversified. To finance its entrepreneurial businesses without diluting its original shareholders, it has issued separate "tracking" stocks for its various wholly-owned divisions: Tissue Repair, Molecular Oncology, and its General division. The financing strategy brings tax advantages and a way to incentivize managers. But skeptics worry that it adds a complexity that will scare off investors.
by Deborah Erickson
Genzyme Corp. is unusual among biotechnology companies, and not just because it turns a profit. The company distinguishes itself...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
